DB001
/ DotBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 07, 2020
EXIT COVID-19: Extracellular Vesicle Infusion Therapy for Severe COVID-19
(clinicaltrials.gov)
- P2; N=60; Not yet recruiting; Sponsor: Direct Biologics, LLC
New P2 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases
1 to 1
Of
1
Go to page
1